Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 13Genitourinary 11Gastrointestinal 9Breast 9Thoracic 4Sarcoma 4Plasma cell 4Lymphoid 4Head & Neck 4Gynecologic 3Other solid neoplasm 2Myeloid 2Dermatologic 2Classical hematology 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 65Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Reverse Transcriptase Polymerase Chain Reaction × CNS × Clear all
NCT00498927 2016-02-29

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
47 enrolled 7 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡